

Peptide 1
NH2
C
C
CH2
CH3
Linker 1
VL
Polypeptide Chain 1
K-coil
(or E-coil)
COOH
C
VH
Linker 2
Linker 4
Linker 3
Linker 3
Polypeptide Chain 2
COOH
C
VH
Linker 2
E-coil
(or K-coil)
VL
NH2
Peptide 1
NH2
C
C
Polypeptide Chain 3
CH2
COOH
CH3
Assembled Fc Diabody
NH2
C
C
NH2
C
C
CH2
COOH
CH3
VL
K-coil (or E-coil)
VH
COOH
C
COOH
C
VH
E-coil (or K-coil)
VL
NH2

Figure 1



Polypeptide Chain 1
COOH
CH3
CH2
Peptide 1
K-coil
(or E-coil)
Linker 4
Linker 3
NH2
VL
VH
Linker 2
Polypeptide Chain 2
Linker 3
COOH
E-coil
(or K-coil)
VH
VL
NH2
Polypeptide Chain 3
CH3
COOH
CH2
Peptide 1
NH2
Assembled Fc Diabody
COOH
CH3
CH2
COOH
CH3
CH2
NH2
NH2
VL
VH
VH
VL
NH2

Figure 2




Figure 3A




Figure 3B




Figure 4A




Figure 4B

GAH IgM μ (anti-µ): 30 µg/ml
+ CD32B x CD79B non-Fc Diabody
+ CD32B x CD79B (ABD) non-Fc Diabody
+ CD32B x CD79B Fc Diabody




Figure 5A




Figure 5B



100
80
60
40
20
0
% Inhibition
Inactive SLE (n=6)
Active SLE (n=8)
CD32B x CD79B ABD
non-Fc Diabody
(100 nM)
CD32B x CD79B
Fc Diabody
(100 nM)

Figure 5C




Figure 6A




Figure 6B



Cumulative Survival (%)
100
80
60
40
20
0
Rx
0
20
40
60
80
100
Days
CD32B x CD79B Fc Diabody (5 mg/kg)
CD32B x CD79B Fc Diabody (10 mg/kg)
Rituximab (5 mg/kg)
PBS

Figure 7